Close Menu

NEW YORK (GenomeWeb) – Meridian Bioscience issued preliminary fiscal year 2016 earnings after the close of the market on Tuesday, reporting a 1 percent year-over-year increase in revenues.

Meridian expects revenues of $196 million for its fiscal year ending Sept. 30, 2016, including fourth quarter revenues of $47 million. Diluted earnings per share should be in the $.75 to $.76 range for the year, compared to $.85 per share in for FY2015.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.